Market Analysis on 26th World Cardiology Conference

Dr. Suresh Vatsyayann

Market Analysis - (2019) Volume 5, Issue 3

Market Analysis on 26th World Cardiology Conference

Dr. Suresh Vatsyayann

The Family Clinic, Gurugram - India, E-mail: freegp@gmail.com

Visit for more related articles at Interventional Cardiology Journal

The market for cardiology technologies reached an estimated $10.2 billion in 2012. According to a new study by Smithers Apex – The Future of Coronary Artery Disease Medical Devices to 2020 – it will grow to $22.5 billion (€20.9 billion) by 2020, with a year-on-year increase of 9.1% Demand for coronary artery disease medical devices will grow through 2021 as clinically viable and costeffective solutions are developed. The report covers three major segments of cardiology surgery, devices and drugs market which includes surgeries, devices and drugs. Cardiovascular diseases are the number one cause of death globally. Some of the major CVDs include coronary heart diseases, , stroke, hypertensive heart diseases, inflammatory heart diseases, rheumatoid heart diseases and others. Coronary heart diseases are the leading cause of death followed by strokes. The prevalence and incidence rate of heart diseases are on a rise; especially in major emerging countries such as India, China and Japan. The market of cardiology surgery, devices and drugs are also on a rise.

In Europe:

The European market for interventional cardiology is leading towards maturity, mostly in Western Europe. Although the economic slowdown had a negative impact on revenues in 2012, it is expected that expanding applications of interventional systems and the popularization of hybrid solutions will drive market growth over the 2013-2017 period.

Market Trends in Europe Interventional Cardiology finds that the market earned approximately $336.7 million in 2012 and estimates this to reach $352.6 million in 2016. Novel applications, the demand for hybrid solutions and the need for new systems in Eastern Europe will fuel market growth.

In America:

Geographically, North America has the highest market share in 2013 due to high awareness about the heart diseases. According to the Centers for Disease Control and Prevention (CDC), every year about 610,000 people in America die of heart diseases. Likewise, annually 735,000 Americans are victims of heart attacks. Thus, increasing of heart attacks in North America would increase the demand of cardiovascular drugs. However, Asia-Pacific region is expected to showcase the fastest growth rate in the future due to rise in aging population, increasing awareness and in other factors.

In Middle East:

Countries in Middle East and Africa bear a heavy burden from Ischemic heart disease. According to, Dubai Health Authority, Heart disease is the cause for every 3 in 10 deaths in the UAE. Huge funding in R&D and various initiatives by government is driving the growth for Ischemic heart Disease market in Middle East and Africa.

Middle-East and Africa Ischemic heart Disease market is growing steadily. The market is growing at the CAGR of 3.1% and expected to reach to US$ 2.84 billion by 2022.

In Asia:

Around 5 million Americans suffer from heart valve disease every year. Heart disease is considered as one of the leading cause of mortality. Thus, substantial rise in burden of heart valve disease is the major growth driver for the heart valve device market. Geographically, this report split Asia-Pacific into several key Regions, with sales (MT), revenue (Million USD), and market share and growth rate of Ischemic Heart Disease Drugs for these regions, from 2012 to 2022.

Importance & Scope

Cardiology is the most interesting one among them and it associated with anything that concerns a human heart. A heart is one of the essential parts of human body and science states that a life without heart is impossible. Hence, Cardiologists are extremely in demand and there is a huge rise in heart-related diseases as days pass.

Cardiac research is key for developing new medicines and treatments for heart disease. The Memorial Care Heart & Vascular Institute at Long Beach Medical Center (MHVI) is one of California's most comprehensive centers for cardiovascular disease and has pioneered innovative heart research. This includes treadmill stress testing, medication advancements that have minimized damage caused by heart attacks and heart pacemakers that are now used all over the world. Cardiac research studies are performed not only for heart health today, but for the heart health of generations.

Through cardiac research, many of the newest and best treatment opportunities and technologies are made available for patients. By participating in research studies, patients are able to play an active role in their personal health and build a relationship with doctors and care teams other than their primary care physicians to come.

Target Audience

• Directors, CEO’s of Organizations

• Business Development Managers

• Chief Scientific Officers

• R&D Researchers

• Professors, Associate Professors, Assistant Professors

• PhD Scholars

• Patent Attorneys

• Investment Analysts

• Association, Association presidents and professionals

• Noble laureates in Cardiology

• Cardiologists